Mahkam Zanganeh - 09 Jun 2023 Form 4/A - Amendment Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Director
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 09 Jun 2023
Net transactions value: +$177,669
Form type: 4/A - Amendment
Filing time: 06 Jul 2023, 20:30:05 UTC
Date Of Original Report: 13 Jun 2023
Previous filing: 06 Jun 2023
Next filing: 16 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Exercise of in-the-money or at-the-money derivative security	$177,669	+86,668	+20%	$2.05	528,836	09 Jun 2023	Direct	F1
holding	PLSE	Common Stock						27,000	09 Jun 2023	Immediate family member 1
holding	PLSE	Common Stock						14,000	09 Jun 2023	Immediate family member 2
holding	PLSE	Common Stock						107,074	09 Jun 2023	Immediate family member 3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-86,668	-100%	$0.000000^*	0	09 Jun 2023	Common Stock	86,668	$2.05	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The number of shares beneficially owned, as reported on the Form 4 filed on June 13, 2023, erroneously included options held by the Reporting Person.